Home > Insider Trading > Filing (0001209191-21-002393)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1326110	Nantkwest Inc.	NK	Biological Products, (No Disgnostic Substances) (2836)	431979754

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1674905	Sonja Nelson	C/O Nantkwest, Inc. 3530 John Hopkins Court San Diego CA 92121	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-01-04	22,729	$3.07	59,681	No	4	M	Direct
Common Stock	Disposition	2021-01-04	39,271	$13.62	20,410	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-01-04	22,729	$0.00	22,729	$3.07

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
177,271		2028-08-27	No	4	M	Direct

Footnotes

The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 4, 2020.
Represents the weighted average share price of an aggregate total of 39,271 shares sold in the price range of $13.31 to $14.015 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Subject to the award recipient's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the option shall vest as follows: twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on August 27, 2019, and thereafter the remaining shares subject to the option shall vest and become exercisable in equal monthly installments over thirty six (36) months, such that the option will be fully vested and exercisable on August 27, 2022.